Verve Therapeutics (VERV) said Friday the US Food and Drug Administration granted fast track designation for its experimental VERVE-102 treatment for hyperlipidemia and high lifetime cardiovascular risk to lower low-density lipoprotein cholesterol.
The company is testing VERVE-102 in a phase 1b clinical trial. The study's demographic and initial safety and efficacy data are expected in Q2.
Verve Therapeutics shares were up 4.9% in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。